Details of Drug-Drug Interaction
| Drug General Information (ID: DDITHRAN7B) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Magnesium sulfate | Drug Info | Tobramycin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Analgesics | Antibiotics | |||||||
| Structure | |||||||||
| Mechanism of Magnesium sulfate-Tobramycin Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive neuromuscular blocking effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Magnesium sulfate | Tobramycin | |||||||
| Mechanism |
Neuromuscular blocking effects Magnesium |
Neuromuscular blocking effects Aminoglycosides |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Neuromuscular blocking effects | ||||||||
| Factor Description | Neuromuscular blocking agents cause paralysis of affected skeletal muscles by blocking postsynaptic acetylcholine (Nm) receptors, thereby blocking neuromuscular signaling at the neuromuscular junction. Neuromuscular blocking agents can cause the following side effects: muscle paralysis, jaw stiffness, and shortness of breath. Concomitant use of drugs with neuromuscular blocking activity may result in severe and/or prolonged respiratory depression. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Close monitoring for increased or prolonged neuromuscular blockade and respiratory depression is recommended during concomitant use, especially in patients with renal impairment and/or with elevated magnesium levels. It may be advisable to avoid administration of aminoglycosides in infants with hypermagnesemia | ||||||||